Adhera Therapeutics, Inc. (ATRX)
Stock Price: $0.1200 USD
0.0000 (0.00%)
Updated Mar 5, 2021 3:50 PM EST - Market closed
| Market Cap | 1.30M |
| Revenue (ttm) | 132,000 |
| Net Income (ttm) | -8.89M |
| Shares Out | 10.87M |
| EPS (ttm) | -0.82 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 5 |
| Last Price | $0.1200 |
| Previous Close | $0.1200 |
| Change ($) | 0.0000 |
| Change (%) | 0.00% |
| Day's Open | 0.1200 |
| Day's Range | 0.0900 - 0.1200 |
| Day's Volume | 45,152 |
| 52-Week Range | 0.02 - 0.15 |
News
There are no news available yet.
About ATRX
Adhera Therapeutics does not have significant operations. Previously, it was involved in the development and commercialization of drug therapeutics for chronic and acute diseases in the United States. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is headquartered in Wake Forest, North Carolina.
| Industry Biotechnology | |
| CEO Andrew Albert Kucharchuk | Employees 2 |
| Stock Exchange OTCMKTS | Ticker Symbol ATRX |
Financial Performance
In 2019, ATRX's revenue was $252,000, an increase of 231.58% compared to the previous year's $76,000. Losses were -$11.98 million, -28.51% less than in 2018.